Last week the government announced new plans designed to speed up the development and approval of treatments for rare diseases, marking an important step forward for patients and families affected by life-limiting and currently untreatable conditions.
The reforms, announced by the Medicines and Healthcare products Regulatory Agency (MHRA), aim to create faster and more flexible pathways for innovative therapies, including personalised genetic medicines and RNA-based treatments. The announcement aligns closely with the mission of the Oxford-Harrington Rare Disease Centre, a pioneering partnership between the University of Oxford and the Harrington Discovery Institute in the United States, which works to accelerate the translation of scientific discoveries into treatments for rare diseases.
The Centre brings together researchers, clinicians, industry partners and patient groups to overcome the barriers that often prevent promising therapies from reaching patients with rare conditions.
Former UK Prime Minister Lord David Cameron, Chair of the Oxford-Harrington Rare Disease Centre Advisory Board, welcomed the announcement, highlighting the importance of international collaboration and innovation in tackling rare diseases.
Rare diseases affect around 3.5 million people in the UK, yet most conditions still have no approved treatment. Researchers developing therapies for these diseases often face significant scientific, regulatory and financial challenges, particularly because patient populations are small and clinical data can be limited.